BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 19689982)

  • 1. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner.
    Barana A; Amorós I; Caballero R; Gómez R; Osuna L; Lillo MP; Blázquez C; Guzmán M; Delpón E; Tamargo J
    Cardiovasc Res; 2010 Jan; 85(1):56-67. PubMed ID: 19689982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner.
    Amorós I; Barana A; Caballero R; Gómez R; Osuna L; Lillo MP; Tamargo J; Delpón E
    J Mol Cell Cardiol; 2010 Jan; 48(1):201-10. PubMed ID: 19616555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis for a high-potency open-channel block of Kv1.5 channel by the endocannabinoid anandamide.
    Moreno-Galindo EG; Barrio-Echavarría GF; Vásquez JC; Decher N; Sachse FB; Tristani-Firouzi M; Sánchez-Chapula JA; Navarro-Polanco RA
    Mol Pharmacol; 2010 May; 77(5):751-8. PubMed ID: 20133392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CB1 cannabinoid receptor-dependent and -independent inhibition of depolarization-induced calcium influx in oligodendrocytes.
    Mato S; Alberdi E; Ledent C; Watanabe M; Matute C
    Glia; 2009 Feb; 57(3):295-306. PubMed ID: 18814177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophysiological effects of anandamide on rat myocardium.
    Li Q; Ma HJ; Zhang H; Qi Z; Guan Y; Zhang Y
    Br J Pharmacol; 2009 Dec; 158(8):2022-9. PubMed ID: 20050190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
    Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endocannabinoid system: physiology and pharmacology.
    Rodríguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
    Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon.
    Smid SD; Bjorklund CK; Svensson KM; Heigis S; Revesz A
    Eur J Pharmacol; 2007 Dec; 575(1-3):168-76. PubMed ID: 17706636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes.
    Al Kury LT; Voitychuk OI; Ali RM; Galadari S; Yang KH; Howarth FC; Shuba YM; Oz M
    Cell Calcium; 2014 Feb; 55(2):104-18. PubMed ID: 24472666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes.
    Al Kury LT; Voitychuk OI; Yang KH; Thayyullathil FT; Doroshenko P; Ramez AM; Shuba YM; Galadari S; Howarth FC; Oz M
    Br J Pharmacol; 2014 Jul; 171(14):3485-98. PubMed ID: 24758718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons.
    Guo J; Ikeda SR
    Mol Pharmacol; 2004 Mar; 65(3):665-74. PubMed ID: 14978245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.
    Oz M; Jaligam V; Galadari S; Petroianu G; Shuba YM; Shippenberg TS
    J Neurochem; 2010 Mar; 112(6):1454-64. PubMed ID: 20050977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid anandamide inhibits potassium conductance in rat cortical astrocytes.
    Vignali M; Benfenati V; Caprini M; Anderova M; Nobile M; Ferroni S
    Glia; 2009 May; 57(7):791-806. PubMed ID: 19031444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anandamide inhibits FcεRI-dependent degranulation and cytokine synthesis in mast cells through CB
    Cruz SL; Sánchez-Miranda E; Castillo-Arellano JI; Cervantes-Villagrana RD; Ibarra-Sánchez A; González-Espinosa C
    Int Immunopharmacol; 2018 Nov; 64():298-307. PubMed ID: 30243065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
    Di Marzo V; Bisogno T; De Petrocellis L; Melck D; Martin BR
    Curr Med Chem; 1999 Aug; 6(8):721-44. PubMed ID: 10469888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anandamide as an intracellular messenger regulating ion channel activity.
    van der Stelt M; Di Marzo V
    Prostaglandins Other Lipid Mediat; 2005 Sep; 77(1-4):111-22. PubMed ID: 16099396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endocannabinoid system in neurodegeneration.
    Battista N; Fezza F; Finazzi-Agrò A; Maccarrone M
    Ital J Biochem; 2006; 55(3-4):283-9. PubMed ID: 17274532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse.
    Palmer JA; Higuera ES; Chang L; Chaplan SR
    Neuroscience; 2008 Jul; 154(4):1554-61. PubMed ID: 18541380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.
    Reggio PH
    Curr Med Chem; 2010; 17(14):1468-86. PubMed ID: 20166921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum.
    Maccarrone M; Rossi S; Bari M; De Chiara V; Fezza F; Musella A; Gasperi V; Prosperetti C; Bernardi G; Finazzi-Agrò A; Cravatt BF; Centonze D
    Nat Neurosci; 2008 Feb; 11(2):152-9. PubMed ID: 18204441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.